QL1706 Combined With Chemotherapy in the Treatment of Immune-mediated NSCLC

NCT07330596 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

96

Enrollment

OTHER

Sponsor class

Conditions

NSCLC (Advanced Non-small Cell Lung Cancer)

Interventions

DRUG: QL1706 combined with Chemotherapy
DRUG: Chemotherapy

Sponsor

Anhui Provincial Cancer Hospital